Page 1728 - Williams Hematology ( PDFDrive )

1702 Part XI: Malignant Lymphoid Diseases Chapter 104: Mature T-Cell and Natural Killer Cell Lymphomas 1703

3. Vose J, Armitage J, Weisenburger D, et al: International peripheral T-cell and natural 30. Zelenetz A GL, Wierda WG, et al. NCCN Clinical Practice Guidelines in Oncology:
killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol Non-Hodgkin’s Lymphomas. http://www.nccn.org/professionals/physician_gls/pdf/
26:4124–4130, 2008. nhl.pdf: National Comprehensive Cancer Network; 2014:451.
4. Ellin F, Landstrom J, Jerkeman M, et al: Real world data on prognostic factors and treat- 31. Horwitz SM, Advani RH, Bartlett NL, et al: Objective responses in relapsed T-cell lym-
ment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry. phomas with single-agent brentuximab vedotin. Blood 123:3095–3100, 2014.
Blood 124:1570–1577, 2014. 32. Pro B, Advani R, Brice P, et al: Brentuximab vedotin (SGN-35) in patients with relapsed
5. Foss FM, Carson KR, Pinter-Brown L, et al: Comprehensive Oncology Measures for or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin
Peripheral T-Cell Lymphoma Treatment (COMPLETE): First detailed report of pri- Oncol 30:2190–2196, 2012.
mary treatment. Blood 120, 2012. 33. Oki SH, Bartlett NL, Jacobsen E, et al: Safety and efficacy of brentuximab vedotin for
6. Went P, Agostinelli C, Gallamini A, et al: Marker expression in peripheral T-cell lym- treatment of relapsed or refractory mature T/NK-cell lymphomas. Hematol Oncol
phoma: A proposed clinical-pathologic prognostic score. J Clin Oncol 24:2472–2479, 31(Suppl 1):147, 2013.
2006. 34. Smith SD, Bolwell BJ, Rybicki LA, et al: Autologous hematopoietic stem cell trans-
7. Weisenburger DD, Savage KJ, Harris NL, et al: Peripheral T-cell lymphoma, not oth- plantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone
erwise specified: A report of 340 cases from the International Peripheral T-cell Lym- Marrow Transplant 40:239–243, 2007.
phoma Project. Blood 117:3402–3408, 2011. 35. Horwitz SM, Kewalramani T, Hamlin P, et al: Second-line therapy with ICE followed
8. Mansoor A, Pittaluga S, Beck PL, et al: NK-cell enteropathy: A benign NK-cell lymph- by high dose therapy and autologous stem cell transplantation for relapsed/refractory
oproliferative disease mimicking intestinal lymphoma: Clinicopathologic features and peripheral T-cell lymphomas: Minimal benefit when analyzed by intent to treat. Blood
follow-up in a unique case series. Blood 117:1447–1452, 2011. (ASH Annual Meeting Abstracts) 2005; 106: Abstract 2679.
9. Weiss LM, Wood GS, Trela M, et al: Clonal T-cell populations in lymphomatoid papu- 36. Smith SM, Burns LJ, van Besien K, et al: Hematopoietic cell transplantation for systemic
losis. Evidence of a lymphoproliferative origin for a clinically benign disease. N Engl J mature T-cell non-Hodgkin lymphoma. J Clin Oncol 31:3100–3109, 2013.
Med 315:475–479, 1986. 37. Le Gouill S, Milpied N, Buzyn A, et al: Graft-versus-lymphoma effect for aggressive
10. Perry AM, Warnke RA, Hu Q, et al: Indolent T-cell lymphoproliferative disease of the T-cell lymphomas in adults: A study by the Societe Francaise de Greffe de Moelle et de
gastrointestinal tract. Blood 122:3599–3606, 2013. Therapie Cellulaire. J Clin Oncol 26:2264–2271, 2008.
11. Federico M, Rudiger T, Bellei M, et al: Clinicopathologic characteristics of angioimmu- 38. Jacobsen ED, Kim HT, Ho VT, et al: A large single-center experience with allogeneic
noblastic T-cell lymphoma: Analysis of the international peripheral T-cell lymphoma stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced
project. J Clin Oncol 31:240–246, 2013. mycosis fungoides/Sézary syndrome. Ann Oncol 22:1608–1613, 2011.
12. Gallamini A, Stelitano C, Calvi R, et al: Peripheral T-cell lymphoma unspecified 39. Goldberg JD, Chou JF, Horwitz S, et al: Long-term survival in patients with peripheral
(PTCL-U): A new prognostic model from a retrospective multicentric clinical study. T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.
Blood 103:2474–2479, 2004. Leuk Lymphoma 53:1124–1129, 2012.
13. Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, et al: Comparison of four prognostic 40. Zinzani PL, Venturini F, Stefoni V, et al: Gemcitabine as single agent in pretreated T-cell
scores in peripheral T-cell lymphoma. Ann Oncol 22:397–404, 2011. lymphoma patients: Evaluation of the long-term outcome. Ann Oncol 21:860–863, 2010.
14. Savage KJ, Harris NL, Vose JM, et al: ALK− anaplastic large-cell lymphoma is clinically 41. Damaj G, Gressin R, Bouabdallah K, et al: Results from a prospective, open-label, phase
and immunophenotypically different from both ALK+ ALCL and peripheral T-cell II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY trial.
lymphoma, not otherwise specified: Report from the International Peripheral T-Cell J Clin Oncol 31:104–110, 2013.
Lymphoma Project. Blood 111:5496–5504, 2008. 42. Enblad G, Hagberg H, Erlanson M, et al: A pilot study of alemtuzumab (anti-CD52
15. Reimer P, Rudiger T, Geissinger E, et al: Autologous stem-cell transplantation as first- monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory
line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study. peripheral T-cell lymphomas. Blood 103:2920–2924, 2004.
J Clin Oncol 27:106–113, 2009. 43. Farina F, Stasia A, Ceccon M, et al: High response rates to crizotinib in advanced, che-
16. Simon A, Peoch M, Casassus P, et al: Upfront VIP-reinforced-ABVD (VIP-rABVD) is moresistant ALK+ lymphoma patients. Blood 122:368, 2013.
not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of 44. Gambacorti Passerini C, Farina F, Stasia A, et al: Crizotinib in advanced, chemoresistant
the randomized phase III trial GOELAMS-LTP95. Br J Haematol 151:159–166, 2010. anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst 106:djt378, 2014.
17. Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, et al: Intensified alemtuzum- 45. Mosse YP, Lim MS, Voss SD, et al: Safety and activity of crizotinib for paediatric
ab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 22:1595–1600, 2011. patients with refractory solid tumours or anaplastic large-cell lymphoma: A Children’s
18. Kim JG, Sohn SK, Chae YS, et al: Alemtuzumab plus CHOP as front-line chemotherapy Oncology Group phase 1 consortium study. Lancet Oncol 14:472–480, 2013.
for patients with peripheral T-cell lymphomas: A phase II study. Cancer Chemother 46. Odejide O, Weigert O, Lane AA, et al: A targeted mutational landscape of angioimmu-
Pharmacol 60:129–134, 2007. noblastic T-cell lymphoma. Blood 123:1293–1296, 2014.
19. Gallamini A, Zaja F, Patti C, et al: Alemtuzumab (Campath-1H) and CHOP che- 47. Iqbal J, Weisenburger DD, Greiner TC, et al: Molecular signatures to improve diagnosis
motherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lym-
(Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood phoma. Blood 115:1026–1036, 2010.
110:2316–2323, 2007. 48. Piccaluga PP, Fuligni F, De Leo A, et al: Molecular profiling improves classification and
20. Foss FM, Sjak-Shie N, Goy A, et al: A multicenter phase II trial to determine the safety prognostication of nodal peripheral T-cell lymphomas: Results of a phase III diagnostic
and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, accuracy study. J Clin Oncol 31:3019–3025, 2013.
doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: The 49. Criscione VD, Weinstock MA: Incidence of cutaneous T-cell lymphoma in the United
CONCEPT study. Leuk Lymphoma 54:1373–1379, 2013. States, 1973–2002. Arch Dermatol 143:854–859, 2007.
21. Schmitz N, Trumper L, Ziepert M, et al: Treatment and prognosis of mature T-cell and 50. Feldman AL, Dogan A, Smith DI, et al: Discovery of recurrent t(6;7)(p25.3;q32.3)
NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of translocations in ALK-negative anaplastic large cell lymphomas by massively parallel
the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116:3418–3425, genomic sequencing. Blood 117:915–919, 2011.
2010. 51. Parrilla Castellar ER, Jaffe ES, Said JW, et al: ALK-negative anaplastic large cell lym-
22. d’Amore F, Relander T, Lauritzsen GF, et al: Up-front autologous stem-cell transplanta- phoma is a genetically heterogeneous disease with widely disparate clinical outcomes.
tion in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30:3093–3099, 2012. Blood 124:1473–1480, 2014.
23. Mehta N, Maragulia JC, Moskowitz A, et al: A retrospective analysis of peripheral 52. Streubel B, Vinatzer U, Willheim M, et al: Novel t(5;9)(q33;q22) fuses ITK to SYK in
T-cell lymphoma treated with the intention to transplant in the first remission. Clin unspecified peripheral T-cell lymphoma. Leukemia 20:313–318, 2006.
Lymphoma Myeloma Leuk 13:664–670, 2013. 53. Feldman AL, Sun DX, Law ME, et al: Overexpression of Syk tyrosine kinase in periph-
24. Lunning MA, Moskowitz AJ, Horwitz S: Strategies for relapsed peripheral T-cell lym- eral T-cell lymphomas. Leukemia 22:1139–1143, 2008.
phoma: The tail that wags the curve. J Clin Oncol 31:1922–1927, 2013. 54. Attygalle AD, Feldman AL, Dogan A: ITK/SYK translocation in angioimmunoblastic
25. Mak V, Hamm J, Chhanabhai M, et al: Survival of patients with peripheral T-cell lym- T-cell lymphoma. Am J Surg Pathol 37:1456–1457, 2013.
phoma after first relapse or progression: Spectrum of disease and rare long-term survi- 55. Lemonnier F, Couronne L, Parrens M, et al: Recurrent TET2 mutations in peripheral
vors. J Clin Oncol 31:1970–1976, 2013. T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.
26. O’Connor OA, Pro B, Pinter-Brown L, et al: Pralatrexate in patients with relapsed or Blood 120:1466–1469, 2012.
refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin 56. Rudiger T, Weisenburger DD, Anderson JR, et al: Peripheral T-cell lymphoma (exclud-
Oncol 29:1182–1189, 2011. ing anaplastic large-cell lymphoma): Results from the Non-Hodgkin’s Lymphoma Clas-
27. Coiffier B, Pro B, Prince HM, et al: Results from a pivotal, open-label, phase II study of sification Project. Ann Oncol 13:140–149, 2002.
romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic 57. Vose JM: Peripheral T-cell non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am
therapy. J Clin Oncol 30:631–636, 2012. 22:997–1005, x, 2008.
28. O’Connor OA, Masszi T, Savage KJ, et al: Belinostat, a novel pan-histone deacetylase 58. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin’s lympho-
inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): mas: Clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma
Results from the BELIEF trial [abstract]. J Clin Oncol 31:8507, 2013. Classification Project. J Clin Oncol 16:2780–2795, 1998.
29. Horwitz S, Jurczak W, Van Hoof A, et al: Belinostat in relapsed or refractory peripheral 59. Abouyabis AN, Shenoy PJ, Lechowicz MJ, et al: Incidence and outcomes of the periph-
T-cell lymphoma subtype angioimmunoblastic T-cell lymphoma: Results from the piv- eral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 49:2099–2107,
otal BELIEF trial. Hematol Oncol 31(Suppl 1):147, 2013. 2008.

Kaushansky_chapter 104_p1693-1706.indd 1703 9/21/15 12:48 PM